Add-on lamotrigine treatment and plasma glutamate levels in epilepsy: relation to treatment response

Epilepsy Res. 2006 Aug;70(2-3):184-9. doi: 10.1016/j.eplepsyres.2006.05.004. Epub 2006 Jun 9.

Abstract

We investigated the effects of add-on lamotrigine treatment on plasma glutamate (Glu) levels, in 29 epileptic patients. Plasma Glu levels were determined by high-performance liquid chromatography at baseline and at 1 and 3 months post-treatment. In patients with a seizure reduction of > or = 66% a decrease of Glu at month 1 was noted, followed by return to baseline levels at month 3. In the remaining patients a gradual increase of Glu was noted throughout the 3 months of the study. The above findings indicate that an excellent clinical response to add-on lamotrigine may be characterized by a statistically significant, yet transient decrease of plasma Glu levels, while increasing Glu levels may accompany a response that is moderate at best. The combination of lamotrigine with valproate was more frequent in patients with excellent clinical response and tended to result in glutamate decrease.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anticonvulsants / pharmacology
  • Anticonvulsants / therapeutic use*
  • Drug Therapy, Combination
  • Epilepsy / blood
  • Epilepsy / drug therapy*
  • Female
  • Glutamic Acid / blood*
  • Humans
  • Lamotrigine
  • Male
  • Time Factors
  • Triazines / pharmacology
  • Triazines / therapeutic use*
  • Valproic Acid / therapeutic use

Substances

  • Anticonvulsants
  • Triazines
  • Glutamic Acid
  • Valproic Acid
  • Lamotrigine